Barinthus Biotherapeutics (BRNS) Stock Forecast, Price Target & Predictions

BRNS Stock Forecast

Barinthus Biotherapeutics stock forecast is as follows: an average price target of $4.00 (represents a 261.11% upside from BRNS’s last price of $1.11) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

BRNS Price Target

The average price target for Barinthus Biotherapeutics (BRNS) is $4.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $3.00. This represents a potential 261.11% upside from BRNS's last price of $1.11.

BRNS Analyst Ratings

Buy

According to 3 Wall Street analysts, Barinthus Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BRNS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Barinthus Biotherapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 13, 2024	Yi Chen	H.C. Wainwright	$5.00	$1.87	167.38%	351.39%
Jun 13, 2024	Carter Gould	Barclays	$3.00	$1.90	57.89%	170.83%

The latest Barinthus Biotherapeutics stock forecast, released on Jun 13, 2024 by Yi Chen from H.C. Wainwright, set a price target of $5.00, which represents a 167.38% increase from the stock price at the time of the forecast ($1.87), and a 351.39% increase from BRNS last price ($1.11).

Barinthus Biotherapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$4.00
Last Closing Price	$1.11	$1.11	$1.11
Upside/Downside	-100.00%	-100.00%	261.11%

In the current month, the average price target of Barinthus Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Barinthus Biotherapeutics's last price of $1.11. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 13, 2024	Alliance Global Partners	Buy	Buy	Hold
Jun 13, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 13, 2024	Barclays	Overweight	Overweight	Hold
May 20, 2024	Alliance Global Partners	Buy	Buy	Hold

Barinthus Biotherapeutics's last stock rating was published by Alliance Global Partners on Aug 13, 2024. The company gave BRNS a "Buy" rating, the same as its previous rate.

Barinthus Biotherapeutics Financial Forecast

Barinthus Biotherapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$334.00K	$468.00K	$6.46M	$6.17M	$17.06M	$15.02M	$-1.00K	$19.00K	$35.00K
Avg Forecast	$4.56M	$5.00M	$5.48M	$6.00M	$867.50K	$216.90K	$7.89M	$8.65M	$9.48M	$10.38M	$11.38M	$12.47M	$166.67K	$166.67K	$166.67K	$166.67K	$125.00K	$250.00K	$704.25K	$1.40M	$3.31M	$7.80M	$3.71M	$3.71M	$100.00K	$100.00K	$33.33K
High Forecast	$4.56M	$5.00M	$5.48M	$6.00M	$867.50K	$216.90K	$7.89M	$8.65M	$9.48M	$10.38M	$11.38M	$12.47M	$166.67K	$166.67K	$166.67K	$166.67K	$125.00K	$250.00K	$704.25K	$1.40M	$3.31M	$7.80M	$3.71M	$3.71M	$100.00K	$100.00K	$33.33K
Low Forecast	$4.56M	$5.00M	$5.48M	$6.00M	$867.50K	$216.90K	$7.89M	$8.65M	$9.48M	$10.38M	$11.38M	$12.47M	$166.67K	$166.67K	$166.67K	$166.67K	$125.00K	$250.00K	$704.25K	$1.40M	$3.31M	$7.80M	$3.71M	$3.71M	$100.00K	$100.00K	$33.33K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	2	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.47%	0.33%	1.95%	0.79%	4.61%	4.05%	-0.01%	0.19%	1.05%

Barinthus Biotherapeutics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $250.00K, with a low forecast of $250.00K, and a high forecast of $250.00K. BRNS's average Quarter revenue forecast represents a -25.15% decrease compared to the company's last Quarter revenue of $334.00K (Jun 23).

Barinthus Biotherapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	2	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-23.11M	$-13.23M	$-23.65M	$-17.52M	$-22.04M	$7.70M	$15.77M	$2.75M	$-14.80M	$-4.49M	$-15.87M
Avg Forecast	$-3.52M	$-3.85M	$-4.22M	$-4.63M	$-669.14K	$-167.31K	$-6.09M	$-6.67M	$-7.31M	$-8.01M	$-8.78M	$-9.62M	$-128.56K	$-128.56K	$-128.56K	$-128.56K	$-96.42K	$-192.84K	$-543.22K	$-1.08M	$-2.55M	$-6.06M	$-2.88M	$-2.88M	$-77.68K	$-77.68K	$-25.89K
High Forecast	$-3.52M	$-3.85M	$-4.22M	$-4.63M	$-669.14K	$-167.31K	$-6.09M	$-6.67M	$-7.31M	$-8.01M	$-8.78M	$-9.62M	$-128.56K	$-128.56K	$-128.56K	$-128.56K	$-96.42K	$-192.84K	$-543.22K	$-1.08M	$-2.55M	$-6.06M	$-2.88M	$-2.88M	$-77.68K	$-77.68K	$-25.89K
Low Forecast	$-3.52M	$-3.85M	$-4.22M	$-4.63M	$-669.14K	$-167.31K	$-6.09M	$-6.67M	$-7.31M	$-8.01M	$-8.78M	$-9.62M	$-128.56K	$-128.56K	$-128.56K	$-128.56K	$-96.42K	$-192.84K	$-543.22K	$-1.08M	$-2.55M	$-6.06M	$-2.88M	$-2.88M	$-77.68K	$-77.68K	$-25.89K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	239.70%	68.62%	43.53%	16.22%	8.63%	-1.27%	-5.48%	-0.96%	190.53%	57.83%	612.89%

1 analysts predict BRNS's average Quarter EBITDA for Dec 22 to be $-2.55M, with a high of $-2.55M and a low of $-2.55M. This is -133.17% lower than Barinthus Biotherapeutics's previous annual EBITDA (Sep 22) of $7.70M.

Barinthus Biotherapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	2	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-17.44M	$-14.07M	$-23.80M	$-18.18M	$-21.19M	$8.24M	$15.69M	$2.60M	$-15.11M	$-4.56M	$-15.93M
Avg Forecast	$-20.21M	$-20.41M	$-18.82M	$-19.01M	$-17.37M	$-17.55M	$-15.85M	$-16.02M	$-17.95M	$-17.74M	$-17.60M	$-17.65M	$-18.03M	$-17.48M	$-15.86M	$-21.44M	$-19.69M	$-20.89M	$-21.54M	$-19.80M	$-16.76M	$-14.74M	$-12.62M	$-12.10M	$-14.71M	$-28.89M	$-3.06B
High Forecast	$-20.21M	$-20.41M	$-18.82M	$-19.01M	$-17.37M	$-17.55M	$-15.85M	$-16.02M	$-17.95M	$-17.74M	$-17.60M	$-14.19M	$-15.02M	$-17.48M	$-15.86M	$-21.44M	$-17.18M	$-20.89M	$-21.54M	$-19.80M	$-16.76M	$-14.74M	$-12.62M	$-12.10M	$-14.71M	$-28.89M	$-3.06B
Low Forecast	$-20.21M	$-20.41M	$-18.82M	$-19.01M	$-17.37M	$-17.55M	$-15.85M	$-16.02M	$-17.95M	$-17.74M	$-17.60M	$-21.10M	$-20.66M	$-17.48M	$-15.86M	$-21.44M	$-22.19M	$-20.89M	$-21.54M	$-19.80M	$-16.76M	$-14.74M	$-12.62M	$-12.10M	$-14.71M	$-28.89M	$-3.06B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.89%	0.67%	1.10%	0.92%	1.26%	-0.56%	-1.24%	-0.21%	1.03%	0.16%	0.01%

Barinthus Biotherapeutics's average Quarter net income forecast for Dec 22 is $-16.76M, with a range of $-16.76M to $-16.76M. BRNS's average Quarter net income forecast represents a -303.31% decrease compared to the company's last Quarter net income of $8.24M (Sep 22).

Barinthus Biotherapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	2	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$13.73M	$961.00K	$13.13M	$12.14M	$20.31M	$-10.81M	$-6.45M	$3.66M	$9.79M	$1.18M	$12.37M
Avg Forecast	$133.24M	$145.99M	$159.97M	$175.28M	$25.34M	$6.34M	$230.59M	$252.66M	$276.85M	$303.35M	$332.39M	$364.20M	$4.87M	$4.87M	$4.87M	$4.87M	$3.65M	$7.30M	$20.57M	$40.90M	$96.73M	$227.85M	$108.23M	$108.23M	$2.92M	$2.92M	$973.71K
High Forecast	$133.24M	$145.99M	$159.97M	$175.28M	$25.34M	$6.34M	$230.59M	$252.66M	$276.85M	$303.35M	$332.39M	$364.20M	$4.87M	$4.87M	$4.87M	$4.87M	$3.65M	$7.30M	$20.57M	$40.90M	$96.73M	$227.85M	$108.23M	$108.23M	$2.92M	$2.92M	$973.71K
Low Forecast	$133.24M	$145.99M	$159.97M	$175.28M	$25.34M	$6.34M	$230.59M	$252.66M	$276.85M	$303.35M	$332.39M	$364.20M	$4.87M	$4.87M	$4.87M	$4.87M	$3.65M	$7.30M	$20.57M	$40.90M	$96.73M	$227.85M	$108.23M	$108.23M	$2.92M	$2.92M	$973.71K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.76%	0.13%	0.64%	0.30%	0.21%	-0.05%	-0.06%	0.03%	3.35%	0.41%	12.70%

Barinthus Biotherapeutics's average Quarter SG&A projection for Mar 24 is $4.87M, based on 3 Wall Street analysts, with a range of $4.87M to $4.87M. The forecast indicates a -64.55% fall compared to BRNS last annual SG&A of $13.73M (Dec 23).

Barinthus Biotherapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	3	2	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.45	$-0.37	$-0.62	$-0.48	$-0.56	$0.22	$0.42	$0.07	-	$-0.13	$-0.64
Avg Forecast	$-0.51	$-0.52	$-0.48	$-0.48	$-0.44	$-0.45	$-0.40	$-0.41	$-0.46	$-0.45	$-0.45	$-0.45	$-0.46	$-0.44	$-0.40	$-0.54	$-0.50	$-0.53	$-0.55	$-0.50	$-0.43	$-0.38	$-0.32	$-0.31	$-0.38	$-0.74	$-78.38
High Forecast	$-0.51	$-0.52	$-0.48	$-0.48	$-0.44	$-0.45	$-0.40	$-0.41	$-0.46	$-0.45	$-0.45	$-0.36	$-0.38	$-0.44	$-0.40	$-0.54	$-0.44	$-0.53	$-0.55	$-0.50	$-0.43	$-0.38	$-0.32	$-0.31	$-0.38	$-0.74	$-78.38
Low Forecast	$-0.51	$-0.52	$-0.48	$-0.48	$-0.44	$-0.45	$-0.40	$-0.41	$-0.46	$-0.45	$-0.45	$-0.54	$-0.52	$-0.44	$-0.40	$-0.54	$-0.56	$-0.53	$-0.55	$-0.50	$-0.43	$-0.38	$-0.32	$-0.31	$-0.38	$-0.74	$-78.38
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.90%	0.70%	1.13%	0.96%	1.32%	-0.58%	-1.30%	-0.23%	-	0.18%	0.01%

According to 1 Wall Street analysts, Barinthus Biotherapeutics's projected average Quarter EPS for Dec 22 is $-0.43, with a low estimate of $-0.43 and a high estimate of $-0.43. This represents a -293.23% decrease compared to BRNS previous annual EPS of $0.22 (Sep 22).

BRNS Forecast FAQ

Is Barinthus Biotherapeutics a good buy?

Yes, according to 3 Wall Street analysts, Barinthus Biotherapeutics (BRNS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of BRNS's total ratings.

What is BRNS's price target?

Barinthus Biotherapeutics (BRNS) average price target is $4 with a range of $3 to $5, implying a 261.11% from its last price of $1.11. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Barinthus Biotherapeutics stock go up soon?

According to Wall Street analysts' prediction for BRNS stock, the company can go up by 261.11% (from the last price of $1.11 to the average price target of $4), up by 351.39% based on the highest stock price target, and up by 170.83% based on the lowest stock price target.

Can Barinthus Biotherapeutics stock reach $2?

BRNS's average twelve months analyst stock price target of $4 supports the claim that Barinthus Biotherapeutics can reach $2 in the near future.

What are Barinthus Biotherapeutics's analysts' financial forecasts?

Barinthus Biotherapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $17.63M (high $17.63M, low $17.63M), average EBITDA is $-13.597M (high $-13.597M, low $-13.597M), average net income is $-66.788M (high $-66.788M, low $-66.788M), average SG&A $514.93M (high $514.93M, low $514.93M), and average EPS is $-1.694 (high $-1.694, low $-1.694). BRNS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $21.04M (high $21.04M, low $21.04M), average EBITDA is $-16.225M (high $-16.225M, low $-16.225M), average net income is $-78.457M (high $-78.457M, low $-78.457M), average SG&A $614.47M (high $614.47M, low $614.47M), and average EPS is $-1.99 (high $-1.99, low $-1.99).

Did the BRNS's actual financial results beat the analysts' financial forecasts?

Based on Barinthus Biotherapeutics's last annual report (Dec 2023), the company's revenue was $805.11K, which missed the average analysts forecast of $2.48M by -67.53%. Apple's EBITDA was $-83.914M, beating the average prediction of $-1.912M by 4287.97%. The company's net income was $-73.631M, missing the average estimation of $-81.921M by -10.12%. Apple's SG&A was $40M, missing the average forecast of $72.42M by -44.77%. Lastly, the company's EPS was $-1.92, missing the average prediction of $-2.078 by -7.61%. In terms of the last quarterly report (Jun 2023), Barinthus Biotherapeutics's revenue was $334K, missing the average analysts' forecast of $704.25K by -52.57%. The company's EBITDA was $-23.647M, beating the average prediction of $-543K by 4253.10%. Barinthus Biotherapeutics's net income was $-23.802M, beating the average estimation of $-21.542M by 10.49%. The company's SG&A was $13.13M, missing the average forecast of $20.57M by -36.19%. Lastly, the company's EPS was $-0.62, beating the average prediction of $-0.546 by 13.46%